← FDA DRUG APPROVALS

FDA NDA · NDA050520

SPECTROBID

Sponsor: PFIZER

APPLICATION
NDA050520
TYPE
NDA
ORIGINAL APPROVAL
1980-12-22
LATEST ACTION
1992-05-29
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

SPECTROBIDDiscontinued
BACAMPICILLIN HYDROCHLORIDE 400MG · TABLET · ORAL
SPECTROBIDDiscontinued
BACAMPICILLIN HYDROCHLORIDE 800MG · TABLET · ORAL

Approval history

1992-05-29Manufacturing (CMC) · Supplement 10 · standardAP
1983-09-12Manufacturing (CMC) · Supplement 4 · standardAP
1983-09-12Manufacturing (CMC) · Supplement 5 · standardAP
1983-02-02Labeling · Supplement 3 · standardAP
1982-12-29Manufacturing (CMC) · Supplement 2 · standardAP
1982-11-23Manufacturing (CMC) · Supplement 1 · standardAP
1982-07-27Manufacturing (CMC) · Supplement 9 · standardAP
1981-11-23Manufacturing (CMC) · Supplement 8 · standardAP
1981-10-07Manufacturing (CMC) · Supplement 7 · standardAP
1981-04-14Labeling · Supplement 6 · standardAP
1980-12-22Type 1 - New Molecular Entity · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →